Ardian acquires majority stake in Neopharmed Gentili

Following the deal, Mediolanum Farmaceutici will retain a minority stake in the business, and Alessandro Del Bono will be appointed its CEO and chair.

Unquote understands that Ardian invested via LBO Fund VI, which held a €4bn final close in September 2016. In addition to the equity deployed by the fund, a debt package of an undisclosed amount was also provided to finance the deal.

The company will use the fresh capital to further consolidate its market position in Italy, expand its product offering, boost its international growth and strengthen its presence in strategic areas of the pharmaceutical sector via new acquisitions.

Company
Neopharmed Gentili specialises in the research, development, production and distribution of vascular, cardio-metabolic, pneumological, antibiotic, over-the-counter and supplement drugs.

The company was established in Milan in 2011, following the merger between Gentili and Neopharmed. Subsequently, it took over the Italian branch of Belgian business Therabel Gienne Pharma in 2017 and established a partnership with Teva Pharmaceuticals for the development and marketing of its respiratory drugs portfolio. Neopharmed Gentili generated revenues of €192m in 2017.

People
Ardian – Nicolò Saidelli (managing director, head Italy).
Neopharmed Gentili – Alessandro Del Bono (CEO, chair).

Advisers
Equity – Rothschild & Co (corporate finance); Bain (commercial due diligence); PwC (financial due diligence); Gitti & Partners (tax); Giovannelli e Associati (legal).
Company – Four Partners (corporate finance); NCTM (legal).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Buyouts
• Southern Europe
• Healthcare
• Ardian (formerly Axa PE)
• Italy
• PwC